JCE: Portfolio Reconstruction Should Support Continued High Yield And Return


  • Nuveen Core Equity Alpha Fund pays a quarterly dividend, generating strong yield. This yield is likely sustainable over the long term, due to its current investment strategy.
  • JCE is a closed-end fund with a diversified equity portfolio and offers investors an attractive option to invest in dividend-paying large-cap equities in the U.S. market.
  • JCE’s portfolio has a very high turnover of 104 percent, and most stocks among its top equity investments have been included after the pandemic.
  • Since the onset of the pandemic, JCE’s annual average total return has been almost 9.5 percent, a positive impact of its portfolio reconstruction.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »

Mature couple sitting on sofa using digital tablet

Compassionate Eye Foundation/Marcy Maloy/DigitalVision via Getty Images

~ by Snehasish Chaudhuri, MBA (Finance)

Nuveen Core Equity Alpha Fund (NYSE:JCE) is a closed-end fund ("CEF") that invests in stocks of companies operating across various sectors in the U.S. It is a fundamentally strong

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-

Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 

This article was written by

Avisol Capital Partners profile picture
Cautious, low key, disciplined investing in biopharma stocks
Avisol Capital Partners runs the Total Pharma Tracker Seeking Alpha Marketplace service. This is managed by Dr Asok Dutta, BVScAH and Dr Udaya Kumar Maiya, MD Oncologist. The service offers end-to-end research on both investing and trading ideas everyday, and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked.

Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.

If you want to check out our service, go here - https://seekingalpha.com/author/avisol-capital-partners/research

Disclaimer - we are not investment advisors.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.